ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
update
/
details

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

NextEdge Admin

16 Nov 2024

1 min 52 sec

FDA,Approval,American Society of Hematology

GSK plc (NYSE:GSK) announced interim results from the DREAMM-7 Phase 3 trial evaluating Blenrep (belantamab mafodotin) combined with bortezomib and dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma. The trial demonstrated a significant reduction in the risk of death for the Blenrep-BorDex combination compared to the standard of care, daratumumab with BorDex, meeting the key secondary endpoint of overall survival (OS). Detailed findings, including safety data, will be presented at the upcoming American Society of Hematology Annual Meeting.

A Phase 3 study targeting newly diagnosed, transplant-ineligible multiple myeloma patients is expected to start by late 2024 under the DREAMM program. Regulatory filings for Blenrep combinations in relapsed or refractory multiple myeloma, supported by results from DREAMM-7 and DREAMM-8 trials, are underway in the U.S., EU, Japan, UK, Canada, and Switzerland.

In 2022, GSK withdrew Blenrep's U.S. marketing authorization after the DREAMM-3 Phase 3 trial failed to meet FDA Accelerated Approval requirements. However, interim DREAMM-8 results released in June showed Blenrep with pomalidomide and dexamethasone significantly improved progression-free survival compared to bortezomib with pomalidomide and dexamethasone, further bolstering the drug's clinical profile.